

**THE 3<sup>RD</sup> WORLD CONGRESS  
OF THE INTERNATIONAL SOCIETY FOR APHERESIS (ISFA)  
January 11-14, 2001, Taipei, Taiwan**

**Thursday, January 11**

<b>13:30-15:00</b>	<b>Wu Ho-Su Memorial Lecture (Clinical Application of Apheresis)</b>
15:00-15:30	Coffee break
<b>15:30-17:00</b>	<b>Wu Ho-Su Memorial Lecture (Clinical Application of Apheresis)</b>

**Friday, January 12**

<b>08:00-08:40</b>	<b>Opening Ceremony</b>	
<b>08:40-09:20</b>	<b>Plenary Lecture : <i>Nosé Y</i></b>	
09:20-09:40	Coffee break	
<b>09:40-12:00</b>	<b>Apheresis in Neurology</b>	<b>Apheresis in Critical Care</b>
12:00-13:30	Lunch	
<b>13:30-15:00</b>	<b>Apheresis in Immunology</b>	<b>Artificial Liver - I</b>
15:00-15:30	Coffee break	
<b>15:30-17:00</b>	<b>Apheresis in Cancer &amp; Transplantation</b>	<b>Artificial Liver - II</b>
<b>17:00-18:00</b>	<b>Poster Session</b>	

**Saturday, January 13**

<b>08:00-09:20</b>	<b>Plenary Lecture : <i>Yamamoto A, Niki E</i></b>	
09:20-09:40	Coffee break	
<b>09:40-12:00</b>	<b>LDL Apheresis</b>	<b>Apheresis Technology</b>
12:00-13:30	Lunch	
<b>13:30-15:00</b>	<b>Obesity &amp; Dyslipidemia</b>	<b>Apheresis in TTP/HUS</b>
15:00-15:30	Coffee break	
<b>15:30-17:00</b>	<b>Apheresis in Nephrology</b>	<b>Preparative Hemapheresis</b>
<b>17:00-18:00</b>	<b>Poster Session</b>	

**Sunday, January 14**

<b>08:00-09:20</b>	<b>Plenary Lecture: <i>Klinkmann H, Agishi T</i></b>	
09:20-09:40	Coffee break	
<b>09:40-12:00</b>	<b>Apheresis in Asia</b>	<b>Free Radicals</b>

***Thursday, January 11, 2001***

***13:00-17:00***

**WU HO-SU MEMORIAL LECTURE**

*Chairperson: Chiu HC (Taiwan)*

**Apheresis in hematology**

Lian ECY (USA)

**Apheresis in rheumatology**

Sawada K (Japan)

**Apheresis in critical care**

Hirasawa H (Japan)

**Artificial liver**

Hu WS (USA)

**LDL apheresis**

Schuff-Werner P (Germany)

**The role of rheology in haemapheresis**

Borberg H (Germany)

***Friday, January 12, 2001***

***8:40-9:20***

**PLENARY LECTURE**

*Chairperson: Ivanovich P (USA)*

**Review and perspectives of therapeutic apheresis (for end-stage heart failure patients)**

Nosé Y (USA)

***Friday, January 12, 2001***

***9:40-12:00***

**S1 APHERESIS IN NEUROLOGY**

*Chairpersons: Hung TP (Taiwan), Khatri BO (USA)*

**New indications for therapeutic plasma exchange in neurological disorders: based on a critical review of current literature by the American Society for Apheresis**

Weinstein R (USA)

**Antibodies in myasthenia gravis**

Vincent A (UK)

**Immunoabsorption plasmapheresis in myasthenias**

Takamori M, Maruta T (Japan)

**The clearance of anti-acetylcholine receptor antibody by double filtration plasmapheresis in the treatment of myasthenia gravis**

Chiu HC, Yeh JH, Chen WH, Lee MF (Taiwan)

**Therapeutic apheresis in multiple sclerosis**

Khatri, BO (USA)

**Selective removal of CD4+ T cells in treatment of multiple sclerosis**

Shibuya N, Matsuo H, Goto H, Onodera H, Yoshida M, Yamawaki N (Japan)

**How to divide into pathogenic and non-pathogenic antibodies?**

Schneidewind JM, Haase CG, Zettl UK, Ramlow W, Tieß M, Michelsen A, Hebestreit G, Winkler RE, Benecke R (Germany)

**Friday, January 12, 2001**

**9:40-12:00**

**S2 APHERESIS IN SEPSIS AND MULTI-ORGAN FAILURE**

*Chairpersons: Hirasawa H (Japan), Chaudry I (USA)*

**Current topics of apheresis in sepsis**

Kodama M, Hanasawa K, Tani T (Japan)

**Clinical benefits of extracorporeal endotoxin removal in septic patients**

Hanasawa K, Tani T, Tsuzuki H, Endo Y, Oka H, Mori T, Shimizu T, Tabata T, Kodama M (Japan)

**Clinical characteristics of effective cases treated with endotoxin adsorption**

Uriu K, Osajima A, Kamochi M, Kaizu K (Japan)

**Efficacy of continuous hemodiafiltration as a cytokine modulator in critical care**

Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda KI, Kitamura N, Ueno H (Japan)

**Effects of direct endotoxin adsorption (PMX-DHP) on patients with perforative peritonitis when utilized as a cytokine treatment**

Matsuno N, Hama K, Iwamoto H, Uchiyama M, Narumi Y, Kikuchi K, Kozaki K, Degawa H, Ikeda K, Ikeda T, Nagao T (Japan)

**Combined use of direct endotoxin hemoadsorption with continuous hemodiafiltration in postoperative multiple organ failure following urgent abdominal surgery**

Matsuno N, Ikeda T, Ikeda K, Hama K, Iwamoto H, Narumi Y, Kikuchi K, Uchiyama M, Kozaki K, Degawa H, Nagao T (Japan)

**A 6-year experience with peritoneal lavage under local anesthesia in patients with necrotizing enterocolitis perforation**

Lin KJ (Taiwan)

**Friday, January 12, 2001**

**13:30-15:00**

**S3 APHERESIS IN IMMUNOLOGY**

*Chairpersons: Siana GA (USA), Tsuda H (Japan)*

**Leukocytapheresis for the treatment of rheumatoid arthritis patient – comparison with double filtration plasmapheresis and change in adhesion molecule**

Kempe K, Matsuda Y, Yang KS, Moriya Y, Kida I, Yamaji K, Kanai Y, Tsuda H, Hashimoto H (Japan)

**Evaluation of the level of serum soluble CD40 ligand in systemic lupus erythematosus patients treated with plasmapheresis**

Yasuda M, Kon T, Sugimoto K, Sekiya H, Kondo I, Kimura K, Kenpe K, Yamazaki Y, Kim YJ, Yang KS, Kida I, Yamaji K, Kanai Y, Tsuda H, Hashimoto H (Japan)

**Centrifugal leukocyte apheresis is capable inducing remission for patients with active ulcerative colitis refractory to glucocorticoid therapy**

Mamoto A, Ashida T, Nomura M, Ayabe T, Kohgo Y (Japan)

**Treatment of cryoglobulinemia in the United States using different methods of plasmapheresis**

Siami GA, Siami FS (USA)

**Treatment of cold IgM hemagglutinin disease with cryofiltration apheresis using cryoglobulin filter in the United States**

Siami FS, Siami GA (USA)

**Friday, January 12, 2001**

**13:30-15:00**

#### **S4 ARTIFICIAL LIVER – I**

*Chairpersons: Kodama M (Japan), Klinkmann H (Germany)*

**An overview of bioartificial liver – from technology, public safety and bioethics**

Hu WS, Sielaff TD, Ruiz LP, Anderson DK (USA)

**Albumin dialysis MARS® for the extracorporeal treatment of acute and chronic liver failure**

Mitzner SR, Stange J, Klammt S, Peszynski P, Hickstein H, Korten G, Schmidt R (Germany)

**Randomized clinical trials of liver dialysis in treatment of hepatic failure and hepatorenal failure**

Ash SR, Kuczek T, Steczko J, Blake DE, Gingrich CH (USA)

**Recent progress in the treatment of fulminant hepatic failure in Japan**

Yoshida M (Japan)

**Friday, January 12, 2001**

**15:30-17:00**

#### **S5 APHERESIS IN CANCER AND TRANSPLANTATION**

*Chairperson: Agishi T (Japan), Kawamura A (Japan)*

**Ex vivo blood manipulation method for cancer treatment**

Tani T, Mekata E (Japan)

**Induction of antitumor activities in spleen cells from mice and rats activated with immobilized lipopolysaccharide beads**

Abe H, Tani T, Endo Y, Hanasawa K, Kodama M (Japan)

**Apheresis and ABO incompatible renal transplantation**

Matsuno N, Hama K, Iwamoto H, Narumi Y, Kikuchi K, Uchiyama M, Degawa H, Kozaki K, Nagao T (Japan)

**Cryofiltration apheresis for removal of anti-blood group antibodies for major ABO incompatible renal transplantation**

Masuko Y, Arikura J, Tsuchihashi S, Murai N, Kaizu T, Iida JI, Horie T, Tanaka M, Tamaki T, Kukita K, Meguro JI, Yonekawa M, Kawamura A (Japan)

**Friday, January 12, 2001**

**15:30-17:00**

**S6 ARTIFICIAL LIVER – II**

*Chairpersons: Mitzner SR (Germany), Hu WS (USA)*

**The indication and limitation of apheresis therapy in acute hepatic failure**

Horie T, Arikura J, Masuko Y, Tanaka M, Meguro JI, Tamaki T, Kukita K, Yonekawa M, Kawamura A (Japan)

**Outcome of Biological-DT treatment in patients with fulminant hepatic failure**

Ko WJ, Lee PH, Lai MY (Taiwan)

**Push-pull sorbent-based pheresis and hemodiabsorption in treatment of hepatic failure: preliminary results of a clinical trial**

Ash SR, Blake DE, Carr DJ, Harker KD, Levy H (USA)

**Arterial infusion of prostaglandin E<sub>1</sub> (PGE<sub>1</sub>) and apheresis therapy ameliorate the postoperative liver failure**

Asanuma Y, Sato T, Nanjo H, Yasui O, Kurokawa T, Koyama K (Japan)

**Removal of albumin bound drugs in albumin dialysis (MARS) - a new liver support system**

Peszynski P, Majcher-Peszynska J, Klammt S, Hehl EM, Wacke R, Stange J, Mitzner SR, Schmidt R, Drewelow B. (Germany)

**Comparison of immunomodulation effect of hepatic tissue xenograft by cyclosporin a and azathioprine in rabbits**

Gupta RC, Mathur AK, Gupta N, Prasad N, Jain R, Srivastva R (Indian)

**Saturday, January 13, 2001**

**8:00-9:20**

**PLENARY LECTURE**

*Chairpersons: Schuff-Werner P (Germany), Wei YH (Taiwan)*

**Apheresis technology for prevention and regression of atherosclerosis - twenty years experience**

Yamamoto A (Japan)

**Free radicals and disease**

Niki E (Japan)

**Saturday, January 13, 2001**

**9:40-12:00**

## **S7 LDL APHERESIS**

*Chairpersons: Yamamoto A (Japan), Bosch T (Germany)*

**Heparin-free DALI LDL-apheresis in hyperlipidemic patients: efficacy, safety and biocompatibility**

Bosch T, Wendler T, Lennertz A, Heinemann O, Duhr C, Samtleben W (Germany)

**LDL/fibrinogen-precipitation (H.E.L.P) and plaque stabilization due to rapid reduction of multiple coronary risk factors**

Schuff-Werner P, Schettler V, Rexer H, Kohlschein P (Germany)

**Comparison between different modes of treatment in a case of familial homozygous hypercholesterolemia**

Palcoux JB, Meyer M, Jouanel P, Vanlieferhingen P, Malpuech G (France)

**Effect of LDL apheresis on regression of coronary atherosclerosis - Fukuoka LDL apheresis study**

Horiuchi M, Tasaki H, Takatsu H, Nagai Y, Tsutsui M, Kouzuma R, Okazaki M, Nakashima Y, FLAS Group (Japan)

**Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients**

Koga N (Japan)

**Successful LDL apheresis treatment in a FH patient with severe diabetic scleroderma**

Koga N, Sato T (Japan)

***Saturday, January 13, 2001***

***9:40-12:00***

## **S8 APHERESIS TECHNOLOGY**

*Chairpersons: Chang YL (Taiwan), Sueoka A (Japan)*

**Recent membrane technologies for therapeutic apheresis**

Sueoka A (Japan)

**Membranes for blood treatment**

Wiese E, Meierling H (Germany)

**Membranes for therapeutic apheresis**

Nakaji S (Japan)

**Membrane for plasma separation**

Hirata N, Shizume Y, Shirokaze JI, Yoshida M, Yamawaki N (Japan)

**Adsorbent: a determinant for the development of therapeutic apheresis**

Akizawa T (Japan)

***Saturday, January 13, 2001***

***13:30-15:00***

## **S9 OBESITY & DYSLIPIDEMIA**

*Chairpersons: Hong CY (Taiwan), Pan WH (Taiwan)*

**Epidemiology of obesity and dyslipidemia**

Pan WH (Taiwan)

**Life style intervention on dyslipidemia and obesity**

Lin W (Taiwan)

**Chinese herbal medicine on dyslipidemia and atherosclerosis**

Shiao MS (Taiwan)

**Pharmacological approaches for dyslipidemia and obesity**

Caterson ID (Australia)

**Maximal lipid lowering by regular LDL-apheresis**

Schuff-Werner P (Germany)

**Economic issues in managing dyslipidemia and obesity**

Gill T, Crowley S, Dalton A (Australia)

***Saturday, January 13, 2001***

***13:30-15:00***

## **S10 APHERESIS IN TTP/HUS**

*Chairpersons: Dimitrijević G (Yugoslavia), Lian ECY (USA)*

**New insights in thrombotic thrombocytopenic purpura**

Lian ECY (USA)

**Total recovery of acute renal failure after dialysed hemolytic uremic syndrome treated with or without membrane plasma separation**

Müller-Wiefel DE, Tönshoff B, Bulla M, Kuwertz-Bröking E, Balzar E, Klare B, Negel D, Kemper MJ (Germany)

**Severe cardiomyopathy in TTP during pregnancy reversed by plasma exchange and infusion**

Cosmai E, Puzis L, Lian ECY (USA)

**Treatment of HELLP syndrome by use of plasma exchange and hemodiafiltration**

Hanasawa K, Tani T (Japan)

**HELLP syndrome treated with plasma exchange -a case presentation**

Dimitrijević G, Uzurov V, Dimitrijević G, Rakić S (Yugoslavia)

***Saturday, January 13, 2001***

***15:30-17:00***

## **S11 APHERESIS IN NEPHROLOGY**

*Chairpersons: Bambauer R (Germany), Akizawa T (Japan)*

**Therapeutic apheresis for renal disorders**

Kaplan AA (USA)

**Effect of  $\beta$ 2-microglobulin adsorption column on dialysis related amyloidosis**

Abe T, Uchita K, Narukawa N, Hasegawa H, Kaketaka A, Matuo T, Kobata H, Abe T, Akizawa T  
(Japan)

**Rapid and persistent reduction of proteinuria by plasma exchange in a case of steroid-resistant focal segmental glomerulosclerosis**

Ishii E, Ando Y, Tamba K, Masunaga Y, Kusano E, Asano Y (Japan)

**Saturday, January 13, 2001**

**15:30-17:00**

**S12 PREPARATIVE HEMAPHERESIS**

*Chairpersons: Shimizu M (Japan), Lin M (Taiwan)*

**Apheresis and transfusion medicine**

Dimitrijević G, Bogdanović G (Yugoslavia)

**Collection of autologous haematopoietic progenitor cells from peripheral blood in pediatric patients**

Reddy R, Thoreen L, Polland P, Klein R (USA)

**Allogeneic peripheral blood stem cell transplantation in Taiwan---NTUH experience**

Lin DT, Lo SC, Tang JL, Lee TY, Chen YC, Lin KS (Taiwan)

**Autologous peripheral blood stem cell transplantation in breast cancer in Taiwan-NTUH experience**

Lin DT, Lo SC, Yeh KH, Lee TY, Chen YC, Lin KS (Taiwan)

**Studies of the leucodepletion failure of the Haemonetics MCS+ plateletpheresis system with LRF6H filter**

Seghatchian J, Krailadsiri P (UK)

**Sunday, January 14, 2001**

**8:00-9:20**

**PLENARY LECTURE**

*Chairpersons: Nosé Y (USA), Borberg H (Germany)*

**The prospects of apheresis in the 21<sup>st</sup> century by new adsorber technologies**

Klinkmann H (Germany)

**From a birth to the up-to-date of double filtration plasmapheresis**

Agishi T (Japan)

**Sunday, January 14, 2001**

**9:40-12:00**

**S13 APHERESIS IN ASIA**

*Chairpersons: Malchesky PS (USA), Yamamoto A (Japan)*



**Apheresis technologies and clinical applications: an international perspective**

Malchesky PS, Koo AP (USA)

**Recent trends in therapeutic apheresis in Japan: focused on techniques and replacement fluid used in main diseases with apheresis**

Shimizu M, Takenaka M, Scientific Committee of JSFA (Japan)

**Therapeutic apheresis in Taiwan**

Yeh JH (Taiwan)

**Therapeutic apheresis in India**

Srivastava R (India)

**Experience of plasmapheresis in Malaysia**

Chong HT, Tan CT (Malaysia)

**Therapeutic plasmapheresis in Vietnam**

Hinh LD (Vietnam)

***Sunday, January 14, 2001***

***9:40-12:30***

**S14 FREE RADICAL**

*Chairpersons: Miyazawa T (Japan), Wei YH (Taiwan)*

**Mitochondrial DNA mutation and 8-hydroxy 2'-deoxyguanosine as markers of oxidative stress in patients with end-stage renal disease**

Wei YH, Lim PS, Liu CS, Tarnng DC (Taiwan)

**Oxidative stress and chronic renal failure**

Lim PS (Taiwan)

**Phosphatidylcholine hydroperoxide and apheresis**

Kuo TL, Chien CT, Liou SY (Taiwan)

**Ascorbic acid administration selectively diminishes hydrogen peroxide activity in the patients with apheresis**

Liou SY, Chien CT, Kuo TL (Taiwan)

**Adaptation to chronic hypoxia enhanced renal superoxide dismutase activity in rats**

Tsai SY, Chien CT, Ma MC, Chen CF (Taiwan)

**PCOOH as a marker for oxidative stress**

Miyazawa T (Japan)

**Endogenous nitric oxide and bradykinin in noncholinergic airway constriction of guinea pigs.**

Lai YL, Tseng TH (Taiwan)

**Antioxidants and human disease: a neurologist's view point**

Chang CY (Taiwan)

**Monitoring the oxidative stress status of human erythrocytes by laser viscodiffractometer: correlation with biochemical parameters**

Liu TZ (Taiwan)

**De novo demonstration and co-localization of free-radical production and apoptosis formation in rat kidney subjected to ischemia/reperfusion**

Chien CT, Lee PH, Chen CF, Ma MC, Lai MK, Hsu SM (Taiwan)

**POSTER SESSION-I**

*Chairperson: Shibuya N (Japan), Tani T (Japan)*

**Long-time effect of protein a immunoabsorption in myasthenia gravis patients- a nine-years follow-up**

Schneidewind JM, Zettl U K., Ramlow W, Schmidt M, Tieß M, Michelsen A, Hebestreit G, Adam U, Roland E, Winkler, Beneck R (Germany)

**Prethymectomy plasmapheresis in myasthenia gravis**

Hsu RL, Yeh JH, Chen WH, Chiu HC (Taiwan)

**Pulmonary function study on patients with myasthenia gravis treated with plasmapheresis**

Yeh JH, Chen WH, Chiu HC (Taiwan)

**Plasmapheresis in immune disorder of neurosystem**

Wang GX (China)

**Clinical experience in neurological disorder treated with plasmapheresis**

Mei SN, Lin YJ (Taiwan)

**Plasma exchange for HTLV-1 associated myelopathy - a case report**

Narukawa N, Shiizaki K, Shibaji H, Kitabata Y, Okamoto M, Uematu K, Kamimura M, Negi S, Akizawa T (Japan)

**Plasmapheresis in the treatment of painful neuropathy**

Chen WH, Yeh JH, Chiu HC (Taiwan)

**Changes of vasoactive factors in the septic patients during extracorporeal PMX treatment**

Shimizu T, Tani T, Hanasawa K, Tabata T, Mori T, Endo Y (Japan)

**Comparative study on anticoagulants in the septic patients during PMX treatment**

Tsutamoto Y, Hanasawa K, Tani T (Japan)

**Plasmapheresis in the medical ICU**

Yeolekar ME, Hase NK, Trivedi T, Shejale S (India)

**Change of serum matrix metalloproteinase-3 (mmp-3) concentration of patients with rheumatoid arthritis who had plasmapheresis**

Kondo I, Kimura K, Kon T, Sugimoto K, Sekiya H, Yasuda M, Kim YJ, Kenpe K, Yamazaki Y, Yang KS, Kida I, Yamaji K, Tamura N, Kanai Y, Kobayashi S, Tsuda H, Hashimoto H (Japan)

**Therapeutic plasmapheresis for the treatment of pregnant systemic lupus erythematosus patients with antiphospholipid antibodies**

Yang KS, Kon T, Sugimoto K, Sekiya H, Yasuda M, Kondo I, Kimura K, Kenpe K, Kim YJ, Kenpe K, Yamazaki Y, Kida I, Yamaji K, Kanai Y, Tsuda H, Hashimoto H (Japan)

**Plasma pheresis in the treatment of systemic lupus erythematosus-a case report**

Wei G, Gu YF, Zhang CS, Xu XH, Sheng LM, Hu VY, Chen YP (China)

**Effective maintenance leukocytapheresis for patients with ulcerative colitis in steroid dependence or resistance**

Kondo K, Shinoda T, Yoshimoto H, Takazoe M, Hamada T (Japan)

**Off-line leukopheresis system for the treatment of ulcerative colitis**

Fujino M, Tani T, Tsuzuki H, Kondo H, Endo Y, Hanasawa K, Kodama M, Matsuda K (Japan)

**Plasmapheresis for MPO-ANCA positive microscopic polyarteritis**

Kida I, Kenyamaji, Kanai Y, Tsuda H, Hashimoto H (Japan)

**Plasmapheresis in the treatment of rheumatic diseases -- a nine year experience**

Chen TL, Lin M, Lee CS (Taiwan)

**Double filtration plasmapheresis for the treatment of bullous pemphigoid**

Kitabata Y, Sakurane M, Orita H, Oda M, Sumikado S, Ebisu T, Sakaguchi T, Ageta S, Akizawa T (Japan)

**Plasma exchange and hemofiltration for postoperative hepatic failure**

Endo Y, Hanasawa K, Tani T (Japan)

**The efficiency of plasma exchange and continuous hemodiafiltration in patients with fulminant hepatitis**

Iwai M, Suzuki K, Kawakami T, Sato A, Endo R, Takikawa Y, Kato A, Inoue Y (Japan)

**Improvement of hepatic encephalopathy following treatment of fulminant hepatic failure with extracorporeal blood detoxification.**

Huang KW, Ko WJ, Lee PH, Lai MY (Taiwan)

**Plasma exchange in the management of hyperlipidemic pancreatitis**

Chen JH (Taiwan)

**Evaluation of the therapeutic effect of artificial liver support system on severe viral hepatitis**

Jiang YS, Chen YM, Yao JL, Al ET (China)

**POSTER SESSION-II**

*Chairpersons: Srivastava R (India), Liou SY (Taiwan)*

**The effect of double filtration plasmapheresis on lipid levels**

Liou SY, Chen TJ, Lin MP, Shu LC, Chang YL (Taiwan)

**Performance evaluation of plasma fractionation membrane**

Zhao CS, Zhang XH, Yue YL (China)

**IL-8 as a marker of biocompatibility in dialyzed patients**

Lin KJ (Taiwan)

**The hemodynamic effects of the different vascular accesses used for double filtration**

**plasmapheresis**

Yeh JH, Chen WH, Chiu HC (Taiwan)

**Review of 38 cases in CRRT**

Chong SN, Kao MT, Chung WK, Lin CY, Lai MN, Chou MY, Chen CC, Chung SY (Taiwan)

**Plasma endotoxin, TSST-1, and zinc levels in chronic hemodialysis patients.**

Kondo H, Tsutamoto Y, Shimizu T, Fujino M, Tabata T, Hanasawa K, Tani T (Japan)

**Association of serum levels of soluble adhesion molecules and carotid atherosclerosis in dialysis patients**

Lim PS, Wang TH, Lu TC (Taiwan)

**Effect of microfilter for removing endotoxin contamination in dialysis system**

Liou SY, Chen TJ, Chang YL (Taiwan)

**Relationship between serum ferritin levels before apheresis and prognosis in patients with hemophagocytic syndrome**

Nakajima F, Shibahara N, Ueda H, Katsuoka Y (Japan)

**Therapeutic plasma exchange in infant**

Lin M, Chang SL, Chu CF, Chang FC (Taiwan)

**Hyperviscosity as a cause of plasma exchange—NTUH experience**

Lin DT, Lo SC, Lee TY, Huang SY, Wang CH, Chen YC, Tang JL, Lin KS (Taiwan)

**A case of leucodepletion failure in COBE spectra plateletpheresis**

Seghatchian J, Krailadsiri P (UK)

**Comparison of discomfort, knowledge and attitude of platelet and whole-blood donors**

Kim HC (Korea)

**Experience with peripheral blood stem cell collection**

Han KS, Park KU, Kim YH, Hur M, Whang DH (Korea)

**Superoxide generation in urinary bladder subjected to obstruction/relief impairs micturition function**

Lai YJ, Yu HJ, Chien CT, Lai MK, Chen CF (Taiwan)

**The oxygen free radicals in ischemia reperfusion injury of skeletal muscle**

Chien HF, Chien CT, Cheng YJ, Hou SM, Hsu SM (Taiwan)

**Cyclosporine A regulates oxidative stress-induced apoptosis in cardiomyocytes**

Chen HW, Chen WJ, Wang TD, Chien CT (Taiwan)

**The activity of superoxide anion in the experimental glaucoma**

Ko ML, Chen CF, Chien CT (Taiwan)

**Forced expression of bcl-2 and bcl-x<sub>l</sub> by novel water-soluble fullerene, c<sub>60</sub>(glucosamine)<sub>6</sub>, reduces renal ischemia/reperfusion induced oxidative stress**

Chien CT, Chen CF, Hsu SM, Chiang LY, Lai MK (Taiwan)

**Chi-bao-meei-rann-dan reduces hemodialysis induced oxidative stress**

Liou SY, Chien CT, Kuo TL (Taiwan)

**Glutathione s-transferase m1 polymorphisms and increase of 4977 bp deletion of sperm mitochondria in Taiwanese patients with varicocele and subclinical varicocele**

Chen SS, Chang LS, Wei YH (Taiwan)